

EFV versus ATV + RTV, both with ABC-3TC or TDF-FTC
ACTG 5202

EFV versus ATV/r, both with ABC-3TC or TDF-FTC

ACTG 5202: Study Design

Study Design: ACTG 5202

- **Background:** Randomized, phase 3b equivalence trial to evaluate open-label efavirenz against atazanavir + ritonavir, each with either double-blinded abacavir-lamivudine or tenofovir DF-emtricitabine, for initial treatment of HIV.
- **Inclusion Criteria (n = 1857)**
 - Age >16 years
 - Antiretroviral-naive
 - No major resistance mutations
- **Treatment Arms (all medications once daily)**
 - EFV 600 mg + ABC-3TC 600-300 mg
 - ATV 300 mg + RTV 100 mg + ABC-3TC 600-300 mg
 - EFV 600 mg + TDF-FTC 300-200 mg
 - ATV 300 mg + RTV 100 mg + TDF-FTC 300-200 mg

EFV + ABC-3TC

(n = 465)

ATV + RTV + ABC-3TC

(n = 463)

EFV + TDF-FTC

(n=464)


ATV + RTV + TDF-FTC

(n=465)

EFV versus ATV/r, both with ABC-3TC or TDF-FTC

ACTG 5202: Results

Week 48: Virologic Response




Source: Daar ES, et al. *Ann Intern Med.* 2011;154:445-56.

EFV versus ATV/r, both with ABC-3TC or TDF-FTC

ACTG 5202: Results

Week 96: Free of Virologic Failure




*Virologic failure = HIV RNA ≥ 1000 copies/mL between 16 and 24 weeks, or HIV RNA ≥ 200 copies/mL after 24 weeks.

Source: Daar ES, et al. *Ann Intern Med.* 2011;154:445-56.

EFV versus ATV/r, both with ABC-3TC or TDF-FTC

ACTG 5202: Results

Week 48: Analysis of Lipids




Source: Daar ES, et al. Ann Intern Med. 2011;154:445-56.

EFV versus ATV/r, both with ABC-3TC or TDF-FTC

ACTG 5202: Results

Week 48: Change in Creatinine Clearance



Source: Daar ES, et al. Ann Intern Med. 2011;154:445-56.

EFV versus ATV/r with ABC-3TC or TDF-FTC

ACTG 5202: Conclusions

Conclusion: “Atazanavir plus ritonavir and efavirenz have similar antiviral activity when used with abacavir-lamivudine or tenofovir DF-emtricitabine.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.

